Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis

Authors: Yixin Liu, Ru Ji, Jingyong Li, Qiang Gu, Xiulan Zhao, Tao Sun, Jinjing Wang, Jiangbo Li, Qiuyue Du, Baocun Sun

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

The chemokine receptors CXCR4 and CCR7 play an important role in cancer invasion and metastasis. This study investigated the expression of CXCR4, CCR7, CXCL12, CCL21, and EGFR to illustrate the role of these biomarkers in breast cancer metastasis and prognosis.

Methods

The CXCR4, CCR7, CXCL12, CCL21, and EGFR biomarkers were analyzed along with ER, PR, and HER-2/neu in breast cancer tissue microarray (TMA) specimens, including 200 primary breast cancer specimens by immunohistochemistry. Corresponding lymph nodes from the same patients were also examined using the same method.

Results

Together with their CXCL12 and CCL21 ligands, CXCR4 and CCR7 were significantly highly expressed in tumor cells with lymph node (LN) metastasis. Similarly, EGFR was expressed highly in tumors with LN metastasis. The ligands were especially expressed in metastatic tumors than in primary tumors from the same patients. Moreover, the expression of both CXCR4 accompanied by CCR7 and CXCL12 accompanied by CCL21 were up-regulated. Kaplan-Meier survival analysis revealed that patients exhibiting high CXCR4, CCR7, and EGFR expression experienced a shorter survival period compared with those with low expression.

Conclusions

The expression of CXCR4, CCR7, and EGFR may be associated with LN metastasis. Moreover, the expression of these receptors can serve as an indicator of undesirable prognosis in patients with breast cancer.
Appendix
Available only for authorised users
Literature
1.
Hassan S, Baccarelli A, Salvucci O, Basik M: Plasma stromal cell derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res. 2008, 14: 446-454. 10.1158/1078-0432.CCR-07-1189.CrossRef
2.
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRef
3.
Paget S: The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989, 8: 98-101.
4.
Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O, Basik M: The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol. 2009, 175: 66-73. 10.2353/ajpath.2009.080948.CrossRef
5.
Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M: Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007, 18: 1021-1029. 10.1093/annonc/mdm060.CrossRef
6.
Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M: Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol. 2009, 20: 1013-1019. 10.1093/annonc/mdn740.CrossRef
7.
Mattern J, Koanagi R, Volm K: Association of vascular endothelium growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung cancer. Br J Cancer. 1996, 73: 931-934.CrossRef
8.
Zlotnik A: Chemokines and cancer. Int J Cancer. 2006, 119: 2026-2029. 10.1002/ijc.22024.CrossRef
9.
Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM: Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res. 2009, 15: 2962-2970. 10.1158/1078-0432.CCR-08-2495.CrossRef
10.
Wang J, Seethala RR, Zhang Q, Gooding W, van Waes C, Hasegawa H, Ferris RL: Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst. 2008, 100: 502-512. 10.1093/jnci/djn059.CrossRef
11.
Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U, Coupland SE: Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol. 2008, 39: 1751-1755. 10.1016/j.humpath.2008.04.017.CrossRef
12.
Hu J, Deng X, Bian X, Li G, Tong Y, Li Y, Wang Q, Xin R, He X, Zhou G, Xie P, Li Y, Wang JM, Cao Y: The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin Cancer Res. 2005, 11: 4658-4665. 10.1158/1078-0432.CCR-04-1798.CrossRef
13.
Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Tomita S, Ichikawa K, Imura J, Hiraishi H, Fujimori T: Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer. 2008, 98: 1682-1689. 10.1038/sj.bjc.6604363.CrossRef
14.
Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, Drescher D, von Langsdorff C, Domeyer M, Biesterfeld S, Galle PR, Junginger T, Moehler M: Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer. 2006, 6: 290-296. 10.1186/1471-2407-6-290.CrossRef
15.
Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003, 105: 186-189. 10.1002/ijc.11063.CrossRef
16.
Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005, 11: 5686-5693. 10.1158/1078-0432.CCR-05-0014.CrossRef
17.
Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M, Ishigami S, Aikou T: CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer. Int J Oncol. 2009, 35: 19-24. 10.3892/ijo_00000308.CrossRef
18.
Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S: Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol. 2009, 132: 202-210. 10.1309/AJCPK35VZJEWCUTL.CrossRef
19.
Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, Hashimoto Y, Miyake M, Hashida H, Imamura M: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res. 2003, 9: 3406-3412.
20.
Sancho M, Vieira JM, Casalou C, Mesquita M, Pereira T, Cavaco BM, Dias S, Leite V: Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. J Endocrinol. 2006, 191: 229-238. 10.1677/joe.1.06688.CrossRef
21.
Kato M, Kitayama J, Kazama S, Nagawa H: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003, 5: R144-R150. 10.1186/bcr627.CrossRef
22.
Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY: Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast. 2006, 15: 533-539. 10.1016/j.breast.2005.08.034.CrossRef
23.
Blot E, Laberge-Le Couteulx S, Jamali H, Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM, Veyret C: CXCR4 membrane expression in node-negative breast cancer. Breast J. 2008, 14: 268-274. 10.1111/j.1524-4741.2008.00573.x.CrossRef
24.
Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006, 97: 275-283. 10.1007/s10549-005-9121-8.CrossRef
25.
Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Kodama R, Sanke T, Nakamura Y: Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer. 2008, 8: 340-349. 10.1186/1471-2407-8-340.CrossRef
26.
Woo SU, Bae JW, Kim CH, Lee JB, Koo BW: A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol. 2007, 15: 281-285. 10.1245/s10434-007-9595-1.CrossRef
27.
Tarasova NI, Stauber RH, Michejda CJ: Spontaneous and ligandinduced trafficking of CXC-chemokine receptor 4. J Biol Chem. 1998, 273: 15883-15886. 10.1074/jbc.273.26.15883.CrossRef
28.
Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004, 15: 613-617. 10.1093/annonc/mdh136.CrossRef
29.
Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, Nakano H: Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999, 189: 451-460. 10.1084/jem.189.3.451.CrossRef
30.
Kodama J, Hasengaowa , Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y: Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol. 2007, 18: 70-76. 10.1093/annonc/mdl342.CrossRef
31.
Singh S, Singh UP, Grizzle WE, Lillard JW: CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004, 84: 1666-1676. 10.1038/labinvest.3700181.CrossRef
32.
Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA: Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005, 104: 676-681. 10.1002/cncr.21217.CrossRef
33.
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC: Upregulation of CXCR4 is essential for HER2 mediated tumor metastasis. Cancer Cell. 2004, 6: 459-469. 10.1016/j.ccr.2004.09.027.CrossRef
Metadata
Title
Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis
Authors
Yixin Liu
Ru Ji
Jingyong Li
Qiang Gu
Xiulan Zhao
Tao Sun
Jinjing Wang
Jiangbo Li
Qiuyue Du
Baocun Sun
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-16

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue

Research

Single nucleotide polymorphisms in the mitochondrial displacement loop and outcome of esophageal squamous cell carcinoma

Research

Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells

Research

Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization

Research

The roles of p38MAPK and caspase-3 in DADS-induced apoptosis in human HepG2 cells

Research

HSP70: a promising target for laryngeal carcinoma radiaotherapy by inhibiting cleavage and degradation of nucleolin

Research

Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits